A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Inclusion Criteria:

* Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment
* Patient must not be pregnant 3 days prior to enrollment

Exclusion Criteria:

* Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
* Patient has had their spleen removed or has a history of autoimmune disorders
* Patient is a regular user of any illicit drugs or has used within the past year of drug or alcohol abuse
* Patient is pregnant or breastfeeding or is expecting to conceive anytime following the study
* Patient is known to be Human Immunodeficiency Virus (HIV)-seropositive
* Patient has a known history of Hepatitis B or C
* Patient has received a vaccine for any disease or condition within one month of enrollment
* Patient has a primary central nervous system tumor.